Soleno Therapeutics Inc
NASDAQ:SLNO

Watchlist Manager
Soleno Therapeutics Inc Logo
Soleno Therapeutics Inc
NASDAQ:SLNO
Watchlist
Price: 42.2954 USD -0.15% Market Closed
Market Cap: $2.3B

Operating Margin

-90.5%
Current
Improving
by 248.1%
vs 3-y average of -338.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-90.5%
=
Operating Income
$-89.3m
/
Revenue
$98.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-90.5%
=
Operating Income
$-89.3m
/
Revenue
$98.7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Soleno Therapeutics Inc
NASDAQ:SLNO
2.3B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

Lower than 85% of companies in the United States of America
Percentile
15th
Based on 14 112 companies
15th percentile
-90.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Soleno Therapeutics Inc
Glance View

Market Cap
2.3B USD
Industry
Biotechnology

Soleno Therapeutics Inc. is a biopharmaceutical company centered on the pressing needs of rare disease patients, most notably those with Prader-Willi syndrome (PWS). This congenital condition, characterized by an insatiable appetite leading to chronic overeating and subsequent obesity, poses significant health risks. Soleno targets this niche through its pioneering drug candidate, DCCR (diazoxide choline controlled-release), which aims to regulate appetite and improve quality of life for PWS patients. By focusing its primary efforts on this orphan indication, Soleno seeks to capitalize on favorable regulatory designations and expedited pathways, affording them advantages in both development timelines and market exclusivity. The company generates revenue through strategic partnerships, research grants, and potential future product sales, assuming regulatory approval of DCCR. One of their key strategies involves engaging with patient advocacy groups and the broader medical community to underscore the unmet needs in PWS and illustrate the potential of DCCR. Additionally, by exploring broader applications of their core technology, Soleno aims to diversify their pipeline, thus enhancing shareholder value and reinforcing their stronghold in the rare disease pharmaceutical sector. The company’s focus on innovation and collaboration, combined with a keen understanding of the regulatory landscape, positions it to navigate the complexities of biopharmaceutical market competition successfully.

SLNO Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-90.5%
=
Operating Income
$-89.3m
/
Revenue
$98.7m
What is Soleno Therapeutics Inc's current Operating Margin?

The current Operating Margin for Soleno Therapeutics Inc is -90.5%, which is above its 3-year median of -338.6%.

How has Operating Margin changed over time?

Over the last 4 months, Soleno Therapeutics Inc’s Operating Margin has increased from -586.7% to -90.5%. During this period, it reached a low of -586.7% on Jun 30, 2025 and a high of -90.5% on Oct 30, 2025.

Back to Top